Patent application number | Description | Published |
20090215081 | SCREENING METHOD FOR ANTICANCER DRUG - The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with β-catenin/TC4 transcription complex. | 08-27-2009 |
20100092994 | High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification - The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide. | 04-15-2010 |
20100137386 | TNIK INHIBITOR AND THE USE - The present invention relates to compositions and methods for the treatment of cancer patients with Traf2- and Nck-interacting kinase (TNIK) inhibitors. More particularly, the present invention relates to pharmaceutical compositions comprising TNIK inhibitor and a pharmaceutically acceptable carrier, and to methods for treating the TNIK inhibitor administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. | 06-03-2010 |
20100216795 | TNIK INHIBITOR AND THE USE - The present invention relates to Traf2- and Nck-interacting kinase (TNIK) inhibitors, pharmaceutical compositions, and methods for the treatment of cancer patients with TNIK inhibitors. | 08-26-2010 |
20120058204 | USE OF OVER EXPRESSION OF CYSTATHIONINE GAMMA LYASE AS A PROGNOSTIC, DIAGNOSTIC AND THERAPEUTIC TARGET FOR CANCER - The present invention relates to a method of identifying an expression level of cystathionine gamma lyase (CTH) in a sample from a subject. The present invention further discloses a method of diagnosing a subject with cancer having risk of resistance to a platinum-based drug. The present invention also discloses a method for improving efficacy of a platinum-based drug in a subject suffering a cancer. | 03-08-2012 |
20130137592 | BIOMARKERS - An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1β, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor. | 05-30-2013 |
20130317218 | NOVEL BICYCLIC THIAZOLE COMPOUNDS - The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). | 11-28-2013 |
20140248261 | ANTIBODY AGAINST MUTANT ALPHA-ACTININ-4 - An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region. | 09-04-2014 |